Acute Kidney Injury Caused by Darunavir in a Patient with COVID-19: A Case Report

Abdalla, Shiema; Elgassim, Lenah; Rustom, Fatima; Othman, Muftah

doi:10.4236/ojneph.2020.104037

Cited by 1 publication

(2 citation statements)

References 11 publications

(9 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Crystal-induced nephropathy and proximal tubulopathy were observed in a 61-year old HIV patient treated with combination therapy including DRV and tenofovir ( Soto et al, 2019 ). Similarly, a case report showed the incidence of acute kidney injury by DRV in a COVID-19 patient ( Abdalla et al, 2020 ). This could be because of the poor solubility of DRV in urine.…”

Section: Antivirals For the Treatment Of Covid-19mentioning

confidence: 93%

“…Adalimumab and sarilumab targets tumor necrosis factor (TNF- α) and IL-6 receptor respectively in COVID-19 ( Patel and Wadhwa, 2021 ). Adalimumab (40 mg along with SoC) has been demonstrated to be safe in CKD and dialysis patients without any impairment of renal function and can be given without dose modification ( Abdalla et al, 2020 ). Similarly, sarilumab (200 mg, i.v.…”

Section: Monoclonal Antibodies For the Treatment Of Covid-19mentioning

confidence: 99%

See 1 more Smart Citation

How to use COVID-19 antiviral drugs in patients with chronic kidney disease

et al. 2023

View full text Add to dashboard Cite

Antiviral drugs such as Remdesivir (Veklury), Nirmatrelvir with Ritonavir (Paxlovid), Azvudine, and Molnupiravir (Lagevrio) can reduce the risk for severe and fatal Coronavirus Disease (COVID)-19. Although chronic kidney disease is a highly prevalent risk factor for severe and fatal COVID-19, most clinical trials with these drugs excluded patients with impaired kidney function. Advanced CKD is associated with a state of secondary immunodeficiency (SIDKD), which increases the susceptibility to severe COVID-19, COVID-19 complications, and the risk of hospitalization and mortality among COVID-19 patients. The risk to develop COVID-19 related acute kidney injury is higher in patients with precedent CKD. Selecting appropriate therapies for COVID-19 patients with impaired kidney function is a challenge for healthcare professionals. Here, we discuss the pharmacokinetics and pharmacodynamics of COVID-19-related antiviral drugs with a focus on their potential use and dosing in COVID-19 patients with different stages of CKD. Additionally, we describe the adverse effects and precautions to be taken into account when using these antivirals in COVID-19 patients with CKD. Lastly, we also discuss about the use of monoclonal antibodies in COVID-19 patients with kidney disease and related complications.

show abstract

Section: Antivirals For the Treatment Of Covid-19mentioning

confidence: 93%

Section: Monoclonal Antibodies For the Treatment Of Covid-19mentioning

confidence: 99%